ArticleNature immunology2023
Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course.
Open access · hybridAbstract read
In one paragraph
Article in Nature immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
17.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 91 citations in OpenAlex.
- Spike Protein at the Crossroads of Long-COVID and Vaccine-Induced Immune Thrombotic Thrombocytopenia Syndromes: A Cardio-Hematological Perspective.Biomedicines · 2026Review
- Structural basis of diverse antibody recognition of conserved coronavirus spike S2 epitopes that contribute to protective immunity.bioRxiv : the preprint server for biology · 2026Article
- Dissociation kinetics and avidity gate SARS-CoV-2 neutralization by HR2 stem helix antibodies.bioRxiv : the preprint server for biology · 2026Article
- β-Cell Dysfunction in COVID-19 and Post-COVID Syndrome: Molecular Mechanisms Linking Inflammation, Oxidative Stress, and Insulin Secretion.International journal of molecular sciences · 2026Review
- Investigation of BOLD signal intensities in long COVID patients using 7T functional MRI.Brain, behavior, & immunity - health · 2026Article
- Longitudinal clinical proteomics reveals pneumonia type-specific protein biomarkers and autoantibodies.JCI insight · 2026Article
- Article
- Clinical and Immunovirological Characteristics Associated with Cardiovascular Dysautonomia in Long COVID.Journal of clinical medicine · 2026Article
- Autoantibodies to IL-1Ra and PGRN in severe COVID-19 are associated with inflammation-induced hyperphosphorylated antigen isoforms.Nature communications · 2026Article
- Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVID.Communications medicine · 2026Article
- Transfer of IgG from long COVID patients induces symptomology in mice.Cell reports. Medicine · 2026Article
- Modulation of Chemokine Activity for Enhanced Angiogenesis and Tissue Regeneration in Chronic Wounds.International journal of molecular sciences · 2026Review
- Proteome-wide autoantibody screening and holistic autoantigenomic analysis unveil COVID-19 signature of autoantibody landscape.BMC immunology · 2026Article
- Exploration of immune phenotypes in self-sampling citizens.iScience · 2026Article
- Longitudinal clinical proteomics reveals pneumonia type-specific protein biomarkers and autoantibodies.medRxiv : the preprint server for health sciences · 2026Article
- Persistent Immune Dysregulation during Long COVID is Manifested in Antibodies Targeting Envelope and Nucleocapsid Proteins.Research square · 2026Article
- Lingering echoes of SARS-CoV-2: mechanistic insights and management of long COVID syndrome.Inflammopharmacology · 2026Review
- Article
- Article
- Divergent biological pathways distinguish community-acquired pneumonia from COVID-19 despite similar plasma cytokine profiles.Respiratory research · 2025Article
Corrections and comments
- Commented on by
- Update of
Authors and funding
46 authors at 12 institutions in 4 countries.
Jonathan Muri *Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0002-6476-3766
Valentina Cecchinato *Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0001-7415-8706
Andrea CavalliInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland. andrea.cavalli@irb.usi.ch.ORCID 0000-0003-4063-4502
Akanksha A ShanbhagInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Milos MatkovicInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Maira BiggiogeroClinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland.
Pier Andrea MaidaClinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland.
Jacques MoritzInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Chiara ToscanoInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Elaheh GhovehoudInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0002-0366-2670
Raffaello FurlanDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Franca BarbicDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.ORCID 0000-0002-8283-1988
Antonio VozaDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Guendalina De NadaiEmergency Medicine Residency School, Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Carlo CerviaDepartment of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-7120-8739
Yves ZurbuchenDepartment of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-5387-9950
Patrick TaeschlerDepartment of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-0522-7629
Lilly A MurrayLyme and Tick-Borne Diseases Research Center at Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0001-6153-5277
Gabriela Danelon-SargentiInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Simone MoroInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Tao GongInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Pietro PiffarettiInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Filippo BianchiniInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Virginia CrivelliInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Lucie PodešvováInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Mattia PedottiInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
David JarrossayInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Jacopo SgrignaniInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Sylvia ThelenInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Mario UhrSynlab Suisse, Bioggio, Switzerland.
Enos BernasconiRegional Hospital Lugano, Ente Ospedaliero Cantonale, Lugano, Switzerland.ORCID 0000-0002-9724-8373
Andri RauchDepartment of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID 0000-0001-5297-6062
Antonio ManzoRheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy.
Adrian CiureaDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-7870-7132
Marco B L RocchiDepartment of Biomolecular Sciences, Biostatistics Unit, University of Urbino, Urbino, Italy.
Luca VaraniInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0002-0963-0987
Bernhard MoserDivision of Infection & Immunity, Cardiff University School of Medicine, Cardiff, UK.
Barbara BottazziIRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0002-1930-9257
Marcus ThelenInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0002-3443-1605
Brian A FallonLyme and Tick-Borne Diseases Research Center at Columbia University Irving Medical Center, New York, NY, USA.
Onur BoymanDepartment of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-8279-5545
Alberto MantovaniDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.ORCID 0000-0001-5578-236X
Christian GarzoniInternal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.
Alessandra Franzetti-PellandaClinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland.
Mariagrazia UguccioniInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland. mariagrazia.uguccioni@irb.usi.ch.ORCID 0000-0002-9570-7011
Davide F RobbianiInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland. drobbiani@irb.usi.ch.ORCID 0000-0001-7379-3484
Università della Svizzera italiana · CHHumanitas University · ITUniversity of Zurich · CHClinica Luganese Moncucco · CHColumbia University Irving Medical Center · USCardiff University · GBEnte Ospedaliero Cantonale · CHIRCCS Humanitas Research Hospital · ITSIB Swiss Institute of Bioinformatics · CHUniversity of Bern · CHUniversity of Pavia · ITUniversity of Urbino · IT
Funding
Understanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI RAVETCH, JEFFREY VICTOR · 2014 to 2023
$26.0MUniversity of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3MVirology CoreP01AI138938 · NIAID · ROCKEFELLER UNIVERSITY · PI BJORKMAN, PAMELA J · 2018 to 2022
$8.4MNIAID NIH HHS P01 AI138938NIAID NIH HHS U01 AI151698NIAID NIH HHS U19 AI111825Swiss National Science Foundation 198431Wellcome Trust 201369
Abstract
Infection with severe acute respiratory syndrome coronavirus 2 associates with diverse symptoms, which can persist for months. While antiviral antibodies are protective, those targeting interferons and other immune factors are associated with adverse coronavirus disease 2019 (COVID-19) outcomes. Here we discovered that antibodies against specific chemokines were omnipresent post-COVID-19, were associated with favorable disease outcome and negatively correlated with the development of long COVID at 1 yr post-infection. Chemokine antibodies were also present in HIV-1 infection and autoimmune disorders, but they targeted different chemokines compared with COVID-19. Monoclonal antibodies derived from COVID-19 convalescents that bound to the chemokine N-loop impaired cell migration. Given the role of chemokines in orchestrating immune cell trafficking, naturally arising chemokine antibodies may modulate the inflammatory response and thus bear therapeutic potential.
Indexed as
COVID-19AutoantibodiesChemokinesHumansPost-Acute COVID-19 SyndromeSARS-CoV-2AutoantibodiesChemokines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.